{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:38:08Z","timestamp":1770680288934,"version":"3.49.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Neoadjuvant chemotherapy followed by radical cystectomy is the standard of care for patients diagnosed with muscle-invasive bladder cancer (MIBC). However, urinary diversion following radical cystectomy significantly reduces patient quality of life. In addition, patients who significantly respond to neoadjuvant chemotherapy have a strong will to preserve the bladder. Bladder-sparing therapy has become a research focus worldwide. Although the bladder-sparing regimen, referred to as trimodality therapy (TMT), has been accepted, the efficacy of immunotherapy combined with chemotherapy for bladder preservation in patients with MIBC has not yet been published. We describe the case of a 50-year-old male presented intermittent macrohematuria and was diagnosed with bladder urothelial carcinoma by diagnostic transurethral resection of bladder tumor (TURBt) with clinical stage IIIA (cT3bN0M0). A complete response was achieved after four courses of neoadjuvant chemotherapy combined with pembrolizumab. Then, we performed a second TURBt plus randomized biopsy by cystoscopy. The pathology indicated no tumor in the bladder. Adjuvant chemoradiotherapy and immunotherapy were subsequently performed. Imaging examinations, cystoscopy and urine tumor DNA (utDNA) levels were used for surveillance after treatment. Finally, the patient achieved bladder preservation and had remained cancer-free for 19 months at the last follow-up on February 20, 2021. This is the first published case study to describe neoadjuvant chemotherapy\u00a0plus pembrolizumab followed by concurrent chemoradiotherapy as a novel bladder-sparing regimen and successfully achieved a promising outcome.<\/jats:p>","DOI":"10.3389\/fimmu.2021.684879","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:52:32Z","timestamp":1623315152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Chuanzhen","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Shou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"Eau Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.082","article-title":"Florida Bladder Cancer Trends 1981 to 2004: Minimal Progress in Decreasing Advanced Disease","volume":"179","author":"Nieder","year":"2008","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.03.075","article-title":"Re: Use of Potentially Curative Therapies for Muscle-Invasive Bladder Cancer in the United States: Results From the National Cancer Data Base","volume":"191","author":"Wood","year":"2014","journal-title":"J\u00a0Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.01.039","article-title":"Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Is Low Among Major European Centres: Results of a Feasibility Questionnaire","volume":"61","author":"Burger","year":"2012","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"59901","DOI":"10.18632\/oncotarget.18316","article-title":"Effectiveness and Safety of PD-1\/PD-L1 Inhibitors in the Treatment of Solid Tumors: A Systematic Review and Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS534","article-title":"Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-Term Outcomes After Bladder-Preserving Tri-Modality Therapy for Patients With Muscle-Invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA Damage Response: Making it Safe to Play With Knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.20.7751-7763.2000","article-title":"RB-Dependent S-Phase Response to DNA Damage","volume":"20","author":"Knudsen","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/nar\/gkg919","article-title":"RB Signaling Prevents Replication-Dependent DNA Double-Strand Breaks Following Genotoxic Insult","volume":"32","author":"Bosco","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-Based Chemotherapy in Muscle-Invasive Bladder Cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.684879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T08:52:34Z","timestamp":1623315154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.684879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2021.684879"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.684879","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"article-number":"684879"}}